Independent analysis puts a QST exenatide lot at 98.4%, against 95.6% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Analytics
The two ionisation techniques in general use produce different charge distributions, different adducts and different failure modes. Certificates almost never say which was used.
Ask a laboratory which ionisation source produced a spectrum and you learn a great deal about the spectrum before you have looked at it. Electrospray on a modern instrument will give a peptide of four thousand daltons a family of multiply charged ions and a mass accuracy in the low parts per million. A linear MALDI time-of-flight will give a single predominantly singly charged ion and an accuracy measured in hundreds of parts per million. Both can answer the question, is this the right compound. Only one of them can answer the question, is this the right compound and nothing very close to it.
It is worth being exact about what a mass spectrometer does, because the imprecision propagates. The instrument generates ions from a sample, separates them according to the ratio of their mass to their charge, and counts them at a detector. The horizontal axis of every spectrum is mass-to-charge, conventionally written m/z and expressed in thomsons or in dimensionless units depending on the vendor’s software. Nothing is weighed. Nothing is measured against a reference mass in the sense that a balance measures against a calibration weight.
What follows from this is that every molecular weight on every certificate of analysis in this market is a calculated quantity, derived from a measured m/z by assigning a charge and subtracting the mass contribution of whatever adducted to the molecule to give it that charge — usually protons, sometimes sodium, occasionally potassium or ammonium. The assignment is normally straightforward and normally correct. It is nonetheless an assignment, and when it goes wrong it goes wrong by an integer factor, which is the kind of error that produces confident nonsense rather than a plausible discrepancy.
The practical consequence for a reader is a habit: when a mass figure appears, ask what was observed and what was inferred. A report that gives both — the m/z, the charge, and the derived neutral mass — has answered the question before it was asked.
Electrospray ionisation works by pumping a solution of the analyte through a fine capillary held at a potential of a few kilovolts relative to the instrument’s entrance. The liquid emerging from the tip forms a cone and then a jet of charged droplets. As solvent evaporates the droplets shrink, the charge density on their surfaces rises, and at the point where electrostatic repulsion exceeds surface tension they fission into smaller droplets. Repeat this enough times and what is left is a bare, charged analyte ion in the gas phase.
Because the charge is acquired in solution and retained through desolvation, a peptide with several basic residues will carry several protons, and the population of ions reaching the analyser is distributed across charge states. This is the defining characteristic of electrospray spectra and the reason they look bewildering to a first-time reader: a single pure compound produces four or five prominent peaks, none of them at the molecular weight.
The distribution is not noise. It carries information about the number of accessible basic sites and about the conformational state of the molecule in solution, and it shifts predictably with mobile-phase composition and pH. It also has a practical advantage that matters for identity work: dividing the mass by three or four brings a large peptide into the range where instruments achieve their best resolving power and accuracy.1
A matching mass has established that the vial contains something of the same elemental composition. That is not identity, and it is not close.
The standing rule in this departmentMatrix-assisted laser desorption ionisation takes a different route. The peptide is mixed with a large molar excess of a small organic compound that absorbs strongly at the laser wavelength — α-cyano-4-hydroxycinnamic acid and sinapinic acid are the usual choices for peptides and proteins respectively — and the mixture is dried on a metal target. A pulsed ultraviolet laser strikes the crystal, the matrix absorbs the energy, and a plume of matrix and analyte is ejected into the vacuum with the analyte largely intact and mostly singly protonated.
Two consequences follow. First, MALDI spectra are simple: one predominant ion per compound, at the molecular weight plus one proton, which makes them easy to read and easy to print on a certificate. Second, MALDI is markedly more tolerant of salts, buffers and heterogeneous samples than electrospray, which is why it survives in routine synthesis monitoring where electrospray would require a chromatographic clean-up first.
The trade-offs are equally real. The matrix produces intense chemical background below roughly a thousand daltons, which obscures small fragments. Ion yield varies between compounds and between spots on the same target, making MALDI a poor quantitative technique. And the achievable mass accuracy on a linear instrument at peptide molecular weights is measured in hundreds of parts per million unless a reflectron and delayed extraction are in use.2
| Element of the identity claim | Certificates stating it (of 20) |
|---|---|
| A mass spectrometric identity test was performed | 14 |
| Both observed and theoretical mass given | 8 |
| Instrument or analyser class named | 6 |
| Ionisation source or mode named | 5 |
| A spectrum reproduced in the document | 5 |
| Charge state of the reported ion stated | 4 |
| Monoisotopic or average convention stated | 3 |
| An acceptance tolerance stated | 3 |
| Peptide mapping or MS/MS performed | 1 |
| Counts are of the most recent certificate supplied to the Journal by each of the twenty companies in the dossier programme as at the last quarterly cycle. A company is credited where the element appears anywhere on the document or on an attached laboratory report. No inference about material quality should be drawn from a documentary count. | |
The choice between the two techniques is not a matter of quality but of question. A synthesis chemist watching a coupling proceed wants a fast, salt-tolerant check that the chain has grown by the expected residue, and MALDI on a bench instrument answers that in minutes. An analytical laboratory asked whether a submitted vial contains the labelled compound and nothing closely related to it needs the resolving power and the accuracy that electrospray into a high-field analyser provides, coupled to a chromatographic separation so that species which co-elute can at least be assigned to retention times.
Both appear in this market, and reports rarely distinguish them. That matters because the two techniques have different blind spots. MALDI can induce loss of labile modifications during desorption, so a phosphorylated or otherwise fragile species may be under-represented. Electrospray suppresses ionisation of some analytes in the presence of others, so a minor component of a mixture may be absent from a spectrum in which it is genuinely present.
A certificate stating the source therefore tells a reader which class of error to consider. The Journal has stopped asking suppliers for more testing and started asking them for this line instead, on the grounds that it costs nothing and changes what the existing test can be said to support.
Because carbon-13 is present at roughly 1.1% natural abundance, a peptide containing one hundred and ninety carbon atoms will exist substantially as molecules containing one, two or three carbon-13 atoms. In a spectrum this appears as a series of peaks above the monoisotopic peak, separated in mass by approximately 1.00336 daltons and distributed in intensity according to the binomial statistics of the composition.
Two things follow, and both are practically useful. First, the spacing between adjacent isotope peaks in a charge-state cluster is one over the charge: a spacing of 0.5 on the m/z axis means the ion is doubly charged, 0.333 means triply, 0.25 means quadruply. This is the simplest charge assignment available and it requires no assumptions about the sample at all. Second, the relative intensities of the isotope peaks are predictable from the elemental composition, so a cluster whose shape departs markedly from the calculated envelope is evidence that two species are overlapping.
Both observations require an instrument capable of resolving the isotope peaks at the relevant m/z, which is where resolving power stops being a specification-sheet number and becomes the thing that determines whether a spectrum can be interpreted at all. Below roughly ten thousand resolving power, a multiply charged peptide envelope collapses into a single broad hump that carries neither the spacing nor the shape information.
Mass accuracy is the difference between the measured mass and the true mass, expressed in parts per million of the measured value. It depends on calibration, on the stability of the instrument’s electronics and temperature, on the number of ions arriving at the detector, and on whether an internal calibrant was co-analysed with the sample. It is not a fixed property of an instrument; it is a property of a measurement made on an instrument on a particular day.
Certificates in this market seldom state a tolerance at all. Where they do, the figure is usually expressed in daltons rather than parts per million and is generous: ±0.5 or ±1.0 dalton is common, which at incretin molecular weights corresponds to 120 to 240 parts per million and is achievable on almost any instrument sold in the last thirty years. A tolerance that no plausible measurement could fail is not an acceptance criterion. It is a formality.
What a meaningful criterion looks like is not mysterious. State the theoretical mass and its convention, state the observed mass, state the deviation in parts per million, and state the limit above which the result would have been reported as non-conforming. Four numbers, all of them already known to the analyst. The compendial framework for validating an analytical procedure asks for exactly this kind of specificity about what a test can discriminate, and the framework predates this market by decades.3
This publication applies one rule to every identity claim it reports, and it is worth stating in isolation because it governs the rest. A mass measurement supports a statement about composition. Only a fragmentation or mapping experiment supports a statement about sequence. Where a source says identity was confirmed, we report that a mass was measured, unless we have seen evidence of the second kind.
The rule has consequences we accept. It makes our coverage read as more sceptical than the underlying documents, because the documents claim more than they establish. It occasionally irritates laboratories which have in fact done sequence-level work and have simply not printed it, and the remedy there is a two-line email which we are glad to receive. And it means we cannot describe any research-grade vial in this market as sequence-confirmed, because on the evidence available to us almost none are.
What the rule is not is an accusation. Nothing in this article suggests that vendors are selling material other than what they label, and the Journal has no evidence of that in respect of any company it covers. The claim is narrower and, we think, harder to argue with: the documentation in general circulation does not have the discriminating power that the language on it implies, and the gap between the two is where every avoidable dispute in this market begins.
The next piece in this department takes the document rather than the instrument as its subject: what a certificate of analysis contains, what it systematically omits, and how to check one in the time it takes to drink a coffee. Identity is one line on that page, and by the standards of the rest of it, one of the better-behaved ones.
A reminder that a purity figure is the output of a method, and that methods differ.
A reminder that a purity figure is the output of a method, and that methods differ.
Deamidation adds 0.98 daltons. On a low-resolution instrument at incretin molecular weights, that is inside the noise.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
The compendial sterility test cannot demonstrate that a batch is sterile. It can only fail a batch that is grossly contaminated. Everything else is process validation.